NCT00320827CompletedPhase 1
Phase 1 Study of CS-1008, a Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), Administered Weekly to Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Daiichi Sankyo
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- To determine the recommended Phase 2 dose
Study Overview
Brief Summary
This is a dose escalation study of CS-1008 (humanized anti-DR5 antibody) to determine the recommended Phase 2 dose and the maximum tolerated dose. Drug will be administered for six weeks and possibly up to 12 weeks depending on response.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically or cytologically diagnosed metastatic solid tumors or lymphomas (with no leukemic component) which are refractory to, not curable with, or not eligible for standard treatment(s).
- •Eighteen years of age or older
- •Eastern Cooperative Oncology Group (ECOG) performance status equal to or less than 2
- •Resolution of any toxic effects (except alopecia) of prior therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 grade of equal to or less than 1
- •Men and women of childbearing potential must be willing to consent to use effective contraception while on treatment and for at least 3 months thereafter.
- •All female patients of childbearing potential must have a negative pregnancy test (serum or urine) within 3 days prior to treatment
- •Patients must be fully informed about their illness and the investigational nature of the study protocol
Exclusion Criteria
- •Anticipation of the need for a major surgical procedure or radiation therapy during the study
- •Treatment with chemotherapy, hormonal therapy, radiotherapy, major surgery, or any investigational agent within 4 weeks (6 weeks for nitrosoureas, mitomycin C, immunotherapy, biological therapy, or major surgery) of study enrollment
- •Cumulative radiation therapy to greater than 25% of the total bone marrow
- •Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) class III or IV congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other clinically significant thromboembolytic event; clinically significant pulmonary disease (e.g., severe chronic obstructive pulmonary disease [COPD] or asthma)
- •Patients with a clinically active brain metastasis (i.e., not treated or still requiring therapy with steroids or radiotherapy [RT]; or with progression 4 weeks after the completion of RT) or an uncontrolled seizure disorder, spinal cord compression, or carcinomatous meningitis
- •Clinically significant active infection which requires antibiotic therapy, or HIV-positive patients receiving antiretroviral therapy.
- •Chronic diarrhea, inflammatory bowel disease, or partial bowel obstruction
Outcomes
Primary Outcomes
To determine the recommended Phase 2 dose
Secondary Outcomes
- To investigate the pharmacokinetics of CS-1008 administered weekly
- To characterize the immunogenicity of CS-1008 by monitoring for anti-CS-1008 antibodies
- To study potential biomarkers of CS-1008 activity
- To make preliminary assessments of anti-tumor effects of CS-1008
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple MyelomaMultiple MyelomaNCT01025206BioInvent International AB35
Recruiting
Phase 1
IKS03 in Patients With Advanced B Cell Non-Hodgkin LymphomasB-cell Non-Hodgkin LymphomaDiffuse Large B Cell LymphomaMantle Cell LymphomaFollicular LymphomaB-cell LymphomaNCT05365659Iksuda Therapeutics Ltd.140
Completed
Phase 1
Study of DS-7080a for the Treatment of Macular DegenerationNeovascular Age-Related Macular DegenerationDiabetic Macular EdemaNCT02530918Daiichi Sankyo56
Completed
Phase 1
Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard TreatmentAdvanced Solid MalignanciesNCT02350868Taipei Medical University23
Recruiting
Phase 1
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic NeoplasmsLeukemia, Myeloid, AcuteMyelodysplastic NeoplasmsNCT06651229Janssen Research & Development, LLC155